echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Innovent Biologics/Baoyuan Medicine Talatinib was included in the breakthrough therapy drug category

    Innovent Biologics/Baoyuan Medicine Talatinib was included in the breakthrough therapy drug category

    • Last Update: 2022-05-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On March 1, Innovent and Baoyuan Medicine jointly announced that Taletrectinib has been included in the list of breakthrough therapy drugs by CDE.


    Talatinib is a new generation of ROS1 and NTRK highly selective and potent tyrosine kinase inhibitors under investigation, which can cross the blood-brain barrier


    In June 2021, Innovent Bio obtained the rights to jointly develop and commercialize the drug with Baoyuan Pharma in Greater China (including mainland China, Hong Kong, Macau and Taiwan) for a total amount of US$189 million


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.